CN Patent

CN117916599A — 生物标记物组合物及其使用方法

Assigned to Siemens Healthcare Diagnostics Inc · Expires 2024-04-19 · 2y expired

What this patent protects

本公开提供了用于鉴定且治疗处于转甲状腺素蛋白淀粉样变心肌病的风险中，或患有转甲状腺素蛋白淀粉样变心肌病的个体的方法和试剂盒。一般而言，一种或多种生物标记物，例如TnI、PKM1、PKM2、NT‑proBNP、RBP4、DCN、TIMP2、SMOC‑2、NfL或其组合的检测或测量，帮助转甲状腺素蛋白淀粉样变心肌病的鉴定。本公开还提供了用于选择患者用于例如用转甲状腺素蛋白稳定剂治疗转甲状腺素蛋白淀粉样变心肌病的方法。

USPTO Abstract

本公开提供了用于鉴定且治疗处于转甲状腺素蛋白淀粉样变心肌病的风险中，或患有转甲状腺素蛋白淀粉样变心肌病的个体的方法和试剂盒。一般而言，一种或多种生物标记物，例如TnI、PKM1、PKM2、NT‑proBNP、RBP4、DCN、TIMP2、SMOC‑2、NfL或其组合的检测或测量，帮助转甲状腺素蛋白淀粉样变心肌病的鉴定。本公开还提供了用于选择患者用于例如用转甲状腺素蛋白稳定剂治疗转甲状腺素蛋白淀粉样变心肌病的方法。

Drugs covered by this patent

acoramidis-hydrochloride (ACORAMIDIS HYDROCHLORIDE)

Patent Metadata

Patent number: CN117916599A
Jurisdiction: CN
Classification: —
Expires: 2024-04-19
Drug substance claim: No
Drug product claim: No
Assignee: Siemens Healthcare Diagnostics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.